Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
12,196 total articles
DRDGOLD (DRD) has the balance sheet and free cash opportunity to convert a near-term gold windfall into processing and infrastructure that would widen margins and reduce unit costs. At today's price of $26.08 the stock offers a reasonable valuation (market cap ~$2.31B, P/E ~9) with upside to $33 over a 180 trading day horizon, while limiting downsi…
Pagaya has turned network growth into cash and profits: $1.3B revenue, positive free cash flow and accelerating ABS sales. The stock trades at a modest market cap of ~$1.72B and valuation multiples (P/S ~1.3x, EV/EBITDA ~7.3x) that look reasonable given 2H momentum. This trade targets a mid-term rebound as revenue and ABS issuance keep closing the …
Paycom (PAYC) looks like a recovering SaaS name with improving technicals, resilient profitability, and a valuation that discounts past growth. I am recommending a mid-term trade: enter at $226.12, target $245.00 (near the 52-week high), stop loss $205.00. Primary horizon: mid term (45 trading days).
Meta looks buyable into AI product momentum and continued ad recovery. The company's MTIA ASIC deployments and an expected Muse commercial push create high-reward catalysts over the next 45-180 trading days. That said, elevated RSI, a premium multiple and looming AI regulation mean this is a tactical buy with strict risk controls.
Ero Copper trades at $33.95 with a $3.48B market cap, but the company’s next leg of growth is concentrated in a small set of project developments. Rising short interest and bearish technicals suggest the market is nervous. This trade idea lays out a mid-term short that assumes a hiccup or execution delay on project ramp-ups will compress the stock …
LuxExperience reported a revenue and EPS beat on 09/16/2026, pushing the stock above its moving averages and into bullish technical momentum. With a $1.30B market cap, PB below 1.0 and concentrated short positioning, this is a tactical long (swing) trade that balances upside to the $11 area against a controlled stop below $8.25. I lay out entry, ta…
We upgrade PBF Energy to a Buy and recommend a mid-term swing trade. Fundamentals - a six-refinery system, strong free cash flow ($670.6M) and an EV/EBITDA of ~4.1 - support upside if refining margins stay firm. Entry $77.12, target $92.00, stop $69.00; horizon: mid term (45 trading days).
Applied Digital (APLD) is a capital-intensive data-center builder that controls rare power capacity and carries a long contract backlog. The stock is volatile and debt-heavy, but the company’s contracted revenue, 3 GW pipeline and 1.4 GW of contracted power create a clear path to meaningful revenue growth as facilities come online in 2027-2028. Thi…
Pagaya Technologies reported meaningful margin expansion and strong free cash flow while the stock has rerated on optimism around ABS distribution and product diversification. The recent pullback offers a tactical long entry at $20.56 with a $30.00 target (180 trading days) and a $17.50 stop. Risk is real - credit cycles, funding shifts, and execut…
Ligand Pharmaceuticals offers a diversified way to own the upside of multiple drug programs without the binary risk of a single clinical asset. The company is trading on a mid-to-high valuation today, but accelerating royalty revenue, a string of investor events and elevated short interest create a tactical long opportunity for patient traders.
Frequency Electronics (FEIM) is a niche leader in precision time and frequency products used across satellites, ground stations and defense platforms. Recent program delays pressured near-term revenue, but a $71 million backlog, strong liquidity metrics and a $100M equity raise provide funding for growth. Technical momentum and a manageable short i…
Generac's long-term supply agreement with Amazon (initial deliveries of $2.4B in 2027-28, upside to $8B through 2033) is a material demand signal for the company's data-center generator business. Given a $1.6B data-center backlog, solid free cash flow, and improved liquidity metrics, the market has underpriced the probability of additional hypersca…
Quantum Computing Inc. is moving from research demonstrations toward commercial deployments via photonics and acquisitions. Revenue growth is real but losses and integration costs are large. With a $1.3B cash cushion, a $42.5M contract backlog and a market cap near $1.9B, we lay out a long trade to capture the next phase of commercialization while …
Solventum appears set to unlock shareholder value by divesting a non-core industrial-solvent unit into a standalone company. The market has likely underappreciated the potential re-rating from a clean balance sheet, clearer growth profile, and a transactional catalyst. We lay out a mid-term trade to capture that revaluation: entry at $12.50, target…
Rheinmetall (RNMBY) trades at a steep multiple but sits on strong backlog growth, structural European rearmament and expanding addressable markets (robotics, smart weapons, ammunition). This trade idea lays out why a controlled long exposure at $235 can work over the next 45 trading days with a $320 target and a $210 stop, while mapping catalysts a…
Coherent's AI/datacenter exposure is driving rapid top-line growth and improving profitability. The market has pulled the stock back recently, creating a tactical long opportunity that banks on margin expansion converting high growth into sustainable earnings and a re-rating. Entry at $300 with a $360 target and $270 stop balances upside from multi…
OptimizeRx sells healthcare workflow and point-of-care messaging into EHRs. Recent product launches (NLAB), senior marketing hires, and network expansion increase high-margin recurring revenue potential. At $7.55 and a market cap near $142M, the stock trades at ~7.8x free cash flow with EV/EBITDA under 9. We recommend a tactical long: entry $7.55, …
Universal Technical Institute (UTI) has been punished after a series of operational stumbles that look correctable. With a market cap around $1.15B, P/E near 33, negative free cash flow but manageable leverage, and technicals showing oversold readings, this is a trade to take on the expectation of operational fixes and enrollment stabilization. Ent…
Rheinmetall sits at the intersection of structural defense demand and near-term execution risk. This note lays out a long-biased trade with precise entry, stop and target levels, explains the fundamental drivers and valuation logic, and highlights catalysts and risks that will move the stock over the next 180 trading days.
Amcor (AMCR) trades at a reasonable multiple with a 6%+ yield, improving free cash flow and industry tailwinds in sustainable packaging. Short-term macro and merger-related noise have pressured the stock; we lay out a trade that captures an income cushion while targeting recovery to prior highs.
Vince (VNCE) just cleared a high hurdle: a Q2 beat and better DTC traction. The OVO acquisition is less an incremental bolt-on than a stress test of a new operating model. If Vince can convert sales mix and protect margins, valuation looks inexpensive relative to its FCF and EV/EBITDA. This is a mid-term swing trade: buy on weakness, size for a 45-…
Pagaya (PGY) is a buy at $20.80. The company pairs strong recent revenue and free-cash-flow generation with below-peer valuation multiples and a shift toward fee-based, asset-light products that reduce interest-rate sensitivity. Entry $20.80, stop $17.00, target $30.00 over a 180-trading-day horizon.
Faeth Therapeutics (FTH) is a clinical-stage immunotherapy company trading at a market cap near $900M. We prefer FTH ahead of a year-end 2026 PIKTOR endometrial cancer (EC) data readout and the program's planned expansion into HR+/HER2- breast cancer. The combination of Fast Track designation, a compact float, and modest short interest creates an a…
Brookfield Asset Management (BAM) offers a 4.3% yield, strong free cash flow ($2.31B) and multiple growth levers including a recent $2.8B acquisition. Near-term technicals are oversold and valuation can re-rate if asset monetization and fee growth accelerate.
Vor Biopharma looks like a funded replication bet: telitacicept delivered a meaningful clinical signal in China and the company has since raised capital to advance global development. At a market cap of about $1.29B and with active short interest, the stock offers a high-risk, high-reward trade if upcoming clinical and execution milestones confirm …
